Range Financial Group LLC Acquires Shares of 55,435 Organon & Co. (NYSE:OGN)

Range Financial Group LLC bought a new position in shares of Organon & Co. (NYSE:OGN) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 55,435 shares of the company’s stock, valued at approximately $827,000.

Other large investors have also recently made changes to their positions in the company. LSV Asset Management lifted its holdings in shares of Organon & Co. by 47.3% in the 2nd quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock worth $136,843,000 after buying an additional 2,121,940 shares during the period. Weiss Asset Management LP bought a new stake in shares of Organon & Co. in the third quarter valued at about $32,966,000. AQR Capital Management LLC lifted its stake in Organon & Co. by 39.8% in the second quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock worth $71,905,000 after acquiring an additional 988,336 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Organon & Co. by 303.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,242,135 shares of the company’s stock worth $23,762,000 after acquiring an additional 934,505 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Organon & Co. by 35.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,323,051 shares of the company’s stock valued at $63,570,000 after purchasing an additional 875,128 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th.

Organon & Co. Stock Up 1.7 %

Organon & Co. stock traded up $0.26 during midday trading on Tuesday, reaching $15.74. The company’s stock had a trading volume of 2,641,994 shares, compared to its average volume of 2,840,377. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The stock has a market capitalization of $4.05 billion, a P/E ratio of 3.12, a PEG ratio of 0.81 and a beta of 0.76. The stock’s 50-day simple moving average is $15.54 and its 200-day simple moving average is $18.51. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same quarter last year, the business earned $0.78 earnings per share. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, sell-side analysts expect that Organon & Co. will post 3.89 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Tuesday, November 12th were given a dividend of $0.28 per share. The ex-dividend date was Tuesday, November 12th. This represents a $1.12 dividend on an annualized basis and a yield of 7.12%. Organon & Co.’s dividend payout ratio is presently 22.22%.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.